FDAnews
www.fdanews.com/articles/108188-biomarck-begins-phase-ii-clinical-study

BioMarck Begins Phase II Clinical Study

July 1, 2008

A Phase II clinical trial is under way for BioMarck Pharmaceuticals’ study of BIO-11006 inhalation solution for chronic obstructive pulmonary disease (COPD). 

The company plans to enroll 162 chronic bronchitis patients who will be administered one of three doses of the drug or placebo in the randomized, double-blind, placebo-controlled trial. To be conducted in 10 centers throughout the U.S., the study will primarily assess patients’ lung function, COPD symptoms and exercise capability.

Biomarck said it expects the first of three cohorts to be completed by the end of the year.